Prof. Keith Kerr is Consultant Pathologist in the Department of Pathology, Aberdeen Royal Infirmary and an Honorary Professor at the University of Aberdeen, Aberdeen, UK. With specialism in thoracic pathology, Prof. Kerr has extensive expertise in NSCLC including: predictive and diagnostic biomarkers (particularly PD-L1 immunohistochemistry), mutations, molecular profiling, immunotherapy, and personalised medicine. Prof. Kerr has collaborated in the development of numerous guidelines for lung cancer diagnosis and management (such as RCPath, SIGN, NICE, BTS, and IASLC/CAP), including work as a lead author for the ESMO Consensus Guidelines on pathology and molecular biomarkers for NSCLC. Furthermore, Prof. Kerr enjoys extensive involvement with IASLC (currently Chair of the Pathology Committee, and Past Board member), is a BTS member of over 30 years; and serves as an Associate Editor for the Journal of Thoracic Oncology.